Abstract
Newborn immaturity transcends their bodies, immune systems, and communication and perception capabilities, making them vulnerable to the environment. Neonatal jaundice is a common condition, with higher levels of unconjugated bilirubin concentration having neurotoxic effects. Newborns are routinely monitored visually or non-invasively with transcutaneous bilirubinometry (TcB) due to their biological immaturity to conjugate bilirubin. Higher levels of bilirubin are a sign that there is either an unusual rate of red blood cells breaking down or that the liver is not able to eliminate bilirubin through bile into the gastrointestinal tract. Actual devices used in bilirubin screening are hand-held and do not allow operation outside the hospital. Based on these factors, a continuous bilirubin monitoring device for newborns was developed, which enables the evaluation of neonatal jaundice inside or outside the hospital. This non-invasive device operates through a mini-spectrometer in the visible range. It was calibrated with phantoms, and its operation was compared with a gold-standard bilirubinometer through in vitro experiments, exploring the practical range of bilirubin variation in newborns and presenting a clinically acceptable deviation of 1 mg/dL. These experiments showed that the continuous bilirubin monitoring device developed has the potential to be used for remote monitoring of jaundice in newborns.